Published in Anesth Analg on April 01, 2007
Repair of a large main pulmonary artery aneurysm in a 71-year-old Jehovah's Witness patient. Tex Heart Inst J (2013) 0.80
Preanesthetic Assessment of the Jehovah's Witness Patient. Ochsner J (2012) 0.79
High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass. J Anesth (2011) 0.77
Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of and for the individual rather than the religious institution. Anesth Analg (2007) 0.76
Optimal care for patients who are Jehovah's Witnesses. Anesth Analg (2007) 0.75
Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med (2010) 6.81
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol (2005) 2.54
Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion (2004) 2.51
Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg (2003) 2.31
The ARCH Projects: design and rationale (IAASSG 001). Eur J Cardiothorac Surg (2013) 2.06
Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology (2010) 1.87
A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology (2005) 1.82
Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg (2011) 1.77
Does perioperative systolic blood pressure variability predict mortality after cardiac surgery? An exploratory analysis of the ECLIPSE trials. Anesth Analg (2011) 1.77
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg (2010) 1.60
Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg (2005) 1.54
The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg (2008) 1.54
Impact of preoperative chronic lung disease on survival after surgical aortic valve replacement. Ann Thorac Surg (2013) 1.52
Positioning an intraaortic balloon pump using intraoperative transesophageal echocardiogram guidance. Anesth Analg (2011) 1.52
Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery. Anesthesiology (2016) 1.51
Contemporary results for proximal aortic replacement in North America. J Am Coll Cardiol (2012) 1.51
The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg (2010) 1.48
A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg (2005) 1.46
The effect and duration of prophylactic platelet transfusions before insertion of a central venous catheter in patients with bone marrow failure evaluated with point-of-care methods and flow cytometry. Anesth Analg (2014) 1.46
The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg (2009) 1.43
Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. Paediatr Anaesth (2015) 1.42
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res (2004) 1.42
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. J Thorac Cardiovasc Surg (2012) 1.42
Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg (2006) 1.41
Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg (2006) 1.39
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Crit Care Med (2007) 1.35
Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev (2011) 1.28
Concepts of blood transfusion in adults. Lancet (2013) 1.28
Selective antegrade cerebral perfusion via right axillary artery cannulation reduces morbidity and mortality after proximal aortic surgery. J Thorac Cardiovasc Surg (2009) 1.27
Off-pump coronary bypass provides reduced mortality and morbidity and equivalent 10-year survival. Ann Thorac Surg (2008) 1.25
Blood coagulation: hemostasis and thrombin regulation. Anesth Analg (2009) 1.24
Moderate hypothermia and unilateral selective antegrade cerebral perfusion: a contemporary cerebral protection strategy for aortic arch surgery. Ann Thorac Surg (2010) 1.24
Descending thoracic aortic aneurysm repair: 12-year experience using distal aortic perfusion and cerebrospinal fluid drainage. Ann Thorac Surg (2005) 1.23
Sepsis-induced disseminated intravascular coagulation, symmetrical peripheral gangrene, and amputations. Crit Care Med (2013) 1.12
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA (2004) 1.07
A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion (2011) 1.07
Long-term outcomes after isolated aortic valve replacement in octogenarians: a modern perspective. Ann Thorac Surg (2008) 1.05
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg (2007) 1.05
Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg (2014) 1.05
Impact of percutaneous coronary intervention performance reporting on cardiac resuscitation centers: a scientific statement from the American Heart Association. Circulation (2013) 1.04
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Res (2013) 1.04
Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology (2008) 1.03
The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg (2005) 1.03
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res (2007) 1.02
Long-term survival for patients with preoperative renal failure undergoing bioprosthetic or mechanical valve replacement. Ann Thorac Surg (2011) 1.00
Axillary cannulation for proximal aortic surgery is as safe in the emergent setting as in elective cases. Ann Thorac Surg (2006) 0.99
Aortic arch surgery using moderate hypothermia and unilateral selective antegrade cerebral perfusion. Ann Cardiothorac Surg (2013) 0.98
A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol (2008) 0.98
Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth (2013) 0.97
Endovascular repair for diverse pathologies of the thoracic aorta: an initial decade of experience. J Am Coll Surg (2009) 0.97
Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion (2013) 0.96
Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis (2011) 0.96
Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesth (2009) 0.96
The impact of specific preoperative organ dysfunction in patients undergoing aortic valve replacement. Ann Thorac Surg (2012) 0.95
Acute aortic dissection with intimal layer prolapse into the left ventricle. Anesth Analg (2007) 0.95
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol (2012) 0.95
The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg (2004) 0.95
Hemiarch replacement at 28°C: an analysis of mild and moderate hypothermia in 500 patients. Ann Thorac Surg (2012) 0.94
Can balloon aortic valvuloplasty help determine appropriate transcatheter aortic valve size? JACC Cardiovasc Interv (2008) 0.94
A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. Anesth Analg (2011) 0.94
Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology (2002) 0.93
The role of thrombin and protease-activated receptors in pain mechanisms. Thromb Haemost (2010) 0.93
Impact of preoperative renal dysfunction in patients undergoing off-pump versus on-pump coronary artery bypass. Ann Thorac Surg (2011) 0.92
A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res (2011) 0.91
The impact of body mass index on morbidity and short- and long-term mortality in cardiac valvular surgery. J Thorac Cardiovasc Surg (2011) 0.91
Acute type a dissection: impact of antegrade cerebral perfusion under moderate hypothermia. Ann Thorac Surg (2013) 0.91
Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg (2008) 0.91
Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg (2011) 0.90
Ileofemoral malperfusion complicating type a dissection: revascularization prevents renal failure. Ann Thorac Surg (2007) 0.90
Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. J Anesth (2007) 0.89
Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery. Transfus Med Rev (2013) 0.88
Risk factors for conversion to cardiopulmonary bypass during off-pump coronary artery bypass surgery. Ann Thorac Surg (2012) 0.88
Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg (2013) 0.87
A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg (2008) 0.87
The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg (2002) 0.87
Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement. Ann Thorac Surg (2011) 0.87
Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg (2004) 0.87
Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg (2010) 0.86
Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease. Anesth Analg (2006) 0.86
Racial disparity persists after on-pump and off-pump coronary artery bypass grafting. Circulation (2009) 0.86